IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals
ISSN 2349-7203
HUMAN

Human Journals
Review Article
January 2022 Vol.:23, Issue:2
© All rights are reserved by Soumik Bhattacharjee et al.

Need for More Coherent Clinical Conveyance of Pharmacovigilance Knowledge to Ameliorate Pediatric Drug Safety

IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals
ISSN 2349-7203
HUMAN

Soumik Bhattacharjee*[1], Rajashree Sabui[2]

1 Dr B.C Roy College of Pharmacy & A.H.S, Durgapur, PIN- 713214, West Bengal. India.

2 Maulana Abul Kalam Azad University of Technology, Haringhata, Nadia, PIN- 741249, West Bengal. India.

Submitted: 24 December 2021
Accepted: 31 December 2021
Published: 30 January 2022

www.ijppr.humanjournals.com

Keywords: Pharmacovigilance, Pediatrics, Adverse drug reactions, Drug Safety, Knowledge translation

ABSTRACT

There is an earnestness to work on the assessment of pediatric medication wellbeing in the pre-market and post-market periods of medication assessment. The need to further develop pharmacovigilance techniques concerns new medications and also existing medications that have been utilized for a long time in an off-mark way in youngsters. Successful strategies for early identification of unfavorable medication responses (ADRs) and medication security epidemiologic investigations are a squeezing need in pediatrics. Additionally, the nature and seriousness of an ADR just to accord with the presumed drug is being utilized, will decide how rapidly the data about hazard should be made accessible to clients and what might be the first and foremost proper strategy for correspondence. Here we will present five vital components that ought to be remembered for pharmacovigilance drives in pediatrics: dynamic ADR reconnaissance; medication or ADR designated pharmacovigilance; prepared observation clinicians; case-control system and normalized methods for acknowledgment; announcing and assessing drug-induced harm. Moreover, connecting pharmacovigilance with pharmacogenomics to observe drug security arrangements is introduced as a promising procedure for the information age. At last, we talk about the significance of an effective interpretation of the pharmacovigilance information into clinical practice to accomplish more secure medication treatment in youngsters.

INTRODUCTION

As of late, it is seen that more than 100,000 patients pass on every year on the planet from appropriately endorsed and used medication therapy[1] is reminiscent of another "chronic drug usage" that is frequently ignored in medical care conveyance – that of unfriendly medication responses (ADRs) which can be much extreme and harder to identify in youngsters. The status of current medication advancement is that clinical preliminaries give proof of viability and starter wellbeing for a prescription at normalized portions in painstakingly developed, homogeneous populaces, while individual patients are dealt with who frequently vary in their reaction to sedate treatment, here and there with obliterating results. ADRs represent 7% of all emergency clinic affirmations[1,2] yet a review audit of ADR announcing shows that under 5% of ADRs are accounted for[3,4]. Of specific concern is the absence of understanding we have of ADRs in youngsters increased by the shortage of far-reaching pediatric-explicit projects pointed toward distinguishing, treating, and forestalling ADRs. It requires a basic need to subsequently further develop pediatric medication security assessment both as in the pre-market just as during post-promoting periods of medication assessment. The requirement to further develop pharmacovigilance strategies concerns new medications as well as existing medications that have been utilized for a long time in an off-mark way in pediatric consideration. Besides, when any danger is recognized it should be viably conveyed to prescribers and patients followed by occasional updates of additional investigations being led to address the at first distinguished security concerns. The nature and seriousness of the ADR, and how broadly the medication is being utilized can be key determinants of how rapidly wellbeing data ought to be made accessible to prescribers and screens of medication treatment. These determinants can likewise illuminate the timetable for administrative activity and the most proper strategy for correspondence to medical services experts and patients[5,6].

The motivation behind this paper is to examine current pharmacovigilance techniques which might straightforwardly affect the protected utilization of medications in youngsters. We propose a few techniques to track down pediatric medication wellbeing arrangements in an ideal and proficient way At last, we examine the significance of an effective interpretation of the pharmacovigilance information into clinical practice to accomplish more secure medication treatment in kids.

Best in Class in Pharmacovigilance:

The World Health Organization (WHO) characterizes pharmacovigilance as the science and exercises connecting with the identification, appraisal, comprehension, and counteraction of antagonistic impacts or some other medication-related issues. Later the utilization of thalidomide came about in extreme intrinsic irregularities in kids brought into the world to numerous ladies utilizing this medication, attention to the significance and need for further developing medication wellbeing has since developed all over the planet. All things considered, to accomplish 'comprehension' and 'anticipation' of ADRs as last objectives, there is as yet a requirement for advancing the current pharmacovigilance strategies and for interpreting all the more effectively the pharmacovigilance information to the clinical practice. A later model is the rofecoxib cardiovascular ADRs from which current pharmacovigilance and regulatory agencies have been emphatically condemned[7]. Restrictions of clinical preliminaries for the incorporation of pregnant ladies and kids are expanded by the way that uncommon unfriendly impacts, deferred impacts, or impacts of long haul drug use are probably going to neglect to be identified during premarketing studies. Nonetheless, it is absurd to expect that new medications be endorsed for market solely after all potential dangers are known. Similarly, as preposterous would be an answer procedure drugs be removed from the market later a first critical ADR is recognized. Each phase of the medication's life cycle requires better pharmacovigilance practices to advance all the more very much informed endorsing also administrative choices. As far as pediatric medication use, worries about drug wellbeing are typically higher and the 'prudent guideline' might be applied before staying away from any damage. In any case, 75% of all meds in the market are not named for pediatric use and just 6% of the medications recorded as the most often utilized in babies and babies convey FDA-supported naming for use in pediatric populations. Multi-focus and worldwide pediatric medication security drives are being sent off as of late and there is as yet a conspicuous hole in the age of data on most medications on the market for their adequacy and security in kids[8,9,10].

Besides, proof age and clinical interpretation of medication security information should be worldwide. While the vast majority of the world's youngsters live in Asian, African, and Latin American nations, most perceived pediatric pharmacology research units are found transcendently in top-level salary nations where the extent of kids is somewhat low. Wellbeing drives ought to permit the exchange of information on pediatric medication security research from created nations to the creating scene[11]. Tragically these nations are

generally where most of the offspring of the world live and where research in pediatric medication security is poor or nonexistent. The world's data set kept up with by the Uppsala Monitoring Center (UMC) called Vigibase, contains all the singular case reports (ICRS) of suspected ADRs that each taking part country gives. In the latest detailing time frame (2005 - 2010), the nations with the biggest quantities of right and dynamic ICRS in the Vigibase per 1 million occupants and year are New Zealand, the United States, Switzerland, Ireland, and the Netherlands. Except for Cuba, which is the main nation recorded inside the top 20 nations that aren't delegated a top-level salary economy country, no African or Latin American portrayal is available. This shortage of data on ADRs worldwide will have genuine ramifications for the medical services of youngsters just as of grown-ups given the known dismalness and mortality from ADRs[12].

Information Generation Strategies in Pediatric Pharmacovigilance:

Creating powerful techniques for early recognition of ADRs in pharmacoepidemiologic studies is a squeezing need in pediatrics. As of late, proposed a technique for the early ID of uncommon yet genuine ADRs utilizing the instance of pemoline[13]. The requirement for more and better-planned medication wellbeing studies becomes apparent on account of chemotherapy for kids with malignant growth. The greater part of the medications utilized in youth disease are off-mark and ought to in this manner fall under the meaning of 'investigational restorative items' requiring full pharmacovigilance techniques, in any event, when pediatric oncologists might have longitudinal involvement in these specialists practically speaking. In any case, since a large portion of these medications are off-patent to date, there are no modern accomplices keen on enrolling a pediatric sign which could prompt the lead of the examinations required and afterward to fitting naming changes[14]. Endurance of youth disease patients has been observed to be roughly 75%. Nonetheless, the instance of youth malignant growth represents very well the effect of long-lasting wellbeing outcomes that may result from ADRs. Indeed, even today, when more kids are enduring malignant growth in light of the expanding viability of chemotherapeutic specialists, a high level of survivors need to live with constant or late happening wellbeing impacts (e.g., coronary illness, lung infection, or hearing misfortune). The lead of investigations of late or long haul impacts of disease drugs in youngsters is in this way vital to work on the protected utilization of medications[15,16].

An undeniable test in the drug security information age in pediatrics is the need for information assortment from various clinical focuses. The production of organizations connecting pediatric focuses through pharmacovigilance data sets is of fundamental significance. This will permit the expansion of test size for any review, which is particularly significant for the recognition of uncommon ADRs or drug security observation in vagrant sickness pediatric subgroups. New advances in quality innovations hold incredible guarantees in understanding medication reaction heterogeneity. The connecting of pharmacogenomic and pharmacovigilance data might be exceptionally useful in recognizing potential medication security arrangements. Accomplishing adequate factual ability to recognize a genuine ADR-biomarker relationship from stochastic commotion is critical[17,18]. We present here four key components that we consider ought to be remembered for pharmacovigilance drives in pediatrics.

1. Active Pediatric ADR Monitoring:

A functioning reconnaissance approach is alluring in pediatric pharmacovigilance studies to produce information quickly and to upgrade the assessment of genuine danger in clinical practice. Due to underreporting inside intentional reconnaissance frameworks and to the impediments of clinical preliminaries in youngsters, the enormous scope of epidemiological assessment of ADR detailing through dynamic observation might be the main solid and predictable wellspring of data on the advantage hazard profile of medications utilized in pediatrics. Obligatory announcing doesn't appear to tackle the issue of underreporting. For instance, in Italy, a functioning checking arrangement of ADRs in youngsters was created through an organization of family pediatricians. Following 1 year of activity, this organization raised the pace of 4 ADRs per 100,000 kids answered to the obligatory Italian framework to a frequency of 15.1 revealed ADRs per 1000 youngsters[19].

Dynamic observation frameworks ought to be viewed as a consistent development just as a reciprocal technique to intentional detailing frameworks. These frameworks can assist with defeating underreporting and when upheld by a normalized approach, that helps in recognition of ADRs, that is the initial step of the pharmacovigilance interaction. More and better revealing should be supported among wellbeing experts yet additionally among patients, since announcing by patients frequently gives more nitty-gritty depictions of what ADRs mean for patients' satisfaction. Hence, increased reporting and more thorough data

collection processes are two outcomes that are likely to occur if active surveillance systems are put in place[20,21,22].

At last, dynamic reconnaissance techniques working inside institutional, public, and worldwide pharmacovigilance projects can serve three significant purposes: a further examination and reinforcing of signs produced by willful detailing frameworks; investigate explicit medication security concerns and interests of wellbeing experts inside the organizations or geological districts; lastly, set up coordinated efforts with administrative offices to be receptive to tranquilize security or general wellbeing crisis circumstances (for example serious security observation of antiviral medications during a flu flare-up)[23,24].

2. Targeted Safety Monitoring:

Until this point in time, the enormous number of medications used to treat pediatric conditions both for authorized or unlicensed utilization makes the legitimate examination of ADRs a titanic mission. Single pharmacovigilance focuses or multicentre networks both face the challenge of restricted accessible assets and the need for a more engaged and designated way to deal with addressing drug wellbeing issues. Conventional unconstrained detailing frameworks are normally not intended to target explicit medications or effectively collaborate with clinicians to investigate their interests and wellbeing needs. In actuality, chronic drug usage designated pharmacovigilance frameworks can be stayed up to date with new medication wellbeing worries as they become known to forefront clinicians. They can be receptive to new data and must have the option to change their information assortment program as fundamental[25,24].

Other potential regions to target pharmacovigilance frameworks' endeavors are the conduction of near investigations for new pediatric items and for pediatric medications expected to be utilized in a drawn-out premise. Drug security worries in pediatric oncology and nervous system science can likewise be effectively tended to if pharmacovigilance communities get assets together with infection-focused networks. Finally, pharmacovigilance programs connected with pharmacogenomic studies to accomplish effective information interpretation to clinical practice, focused on hereditary biomarker disclosure and prescient testing for explicit medications are at this time the main possibly practical procedures[26].

3. Case-Control Methodology:

Most pharmacovigilance information bases in the world are populated simply by reports of ADR cases. The non-appearance of information on control patients matched for age, sexual orientation however in particular for suspected medications, forestalls the affirmation of signs of suspected causality and the distinguishing proof of hazard factors other than the medication. Among the current ADR reconnaissance techniques, case-control concentrates on making the approval and appraisal of medication ADR affiliations conceivable. Consequently, the mix of these investigations with a functioning reconnaissance perspective would be helpful for signal fortifying and hazard factor recognizable proof. Matching cases as precisely as conceivable with controls is not a simple assignment principally at the point when cases show polypharmacy at that point when the ADR happened. Test size for performing affiliation studies might be little at single organizations and in this way multicentre information assortment is fundamental[27,28,29].

Also, to gauge hazard all the more precisely and to work on the comprehension of ADRs in youngsters, all conceivable hazard factors should be distinguished as obviously as conceivable (for example age, sexual orientation, corresponding medications, or hereditary variations) utilizing case-control techniques.

4. Standardized Methodology:

Exact and nitty-gritty clinical information are basic factors in the disclosure of ADR-related biomarkers. Significant clinical ADR information needs to be gathered in a normalized manner to help the complex course of assessing conceivable puzzling elements, for example, infection state, cooperating drugs, and clinical judgment by the ADR reconnaissance clinicians. Besides, the foundation of ADR reconnaissance organizations requires the utilization of tweaked data sets where information should be entered in a predictable way for further examination. Worldwide harmonization of terms utilized in pharmacovigilance should be reinforced too. Correspondence in pharmacovigilance should be clear and steady in any case the reasonable structures important for process improvement are dominated. Formore productive clinical interpretation of medication security information acquired, correspondence between all partners should be productive too[30,31,32].

The exigency for More Effective Knowledge Translation

Successful medication wellbeing information interpretation implies successful correspondence of hazard to all the clinicians engaged with the medication use process (i.e., doctors, drug specialists, attendants), patients, and parental figures. Successful correspondence directs that data should be given in a manner that is valuable to the planned beneficiaries. The transmission of the perfect message, through the proper media, to the right crowd is the significant test of hazard correspondence procedures. In any case, off-name use what's more under-acknowledgment of ADRs via parental figures may additionally be significant reasons for underreporting in youngsters. Because of correspondence restrictions, pediatric patients are more averse to have the option to express a reaction to prescriptions with the equivalent clearness as grown-up patients. Physicians may not know how to search for a specific ADR when it is bound to happen along the course of treatment, nor how to analyze and oversee responses[33,34].

At last, the benefits of patient commitment in pharmacovigilance exercises ought not to be underrated. A two-way correspondence cycle can be agreeably settled between pharmacovigilance focuses and patients or guardians, to expand drug security information and to both illuminate and insight patients and families. Besides, a vast range of pharmacovigilance focuses ought to have a function to illuminate patients and doctors of explicit medication hazards, playing a more dynamic warning and instructive job[35,36].

CONCLUSION:

Kids frequently can't verbally communicate their drug treatment encounters. Therefore, infants, babies, and kids who require medicine for intense, constant, and life-saving therapy are in danger of an assortment of ADRs going from ineffectual treatment and minor ADRs to extreme morbidity also demise. Pediatric pharmacovigilance addresses a central stage in pediatric medication wellbeing appraisal. As referenced before, security information about everyday recommended pediatric medications are regularly restricted and, consequently, post-promoting reconnaissance becomes essential, since it frequently addresses the main dependable technique for surveying drug wellbeing, overall when ADRs are uncommon and huge examples of treated subjects are important to distinguish them. In this scene, youngsters and newborn children address a 'need subjects' class[37,38]. There is a squeezing need for an evidence-based drug treatment approach that tries to limit perilous and for all time crippling ADRs brought about by drug harmfulness in children. The absence of data on pediatric

medication security and viability, joined with insufficient systems for observing and evaluating ADRs brings about a high-hazard circumstance for kids requiring drug treatment[39].For reinforcing attention to the significance of unconstrained reports among medical care experts and inclining toward ADRs reports, WHO perceived a few key measures to be taken. Each neonatologist or pediatrician ought to be enough prepared, by advancing pharmacovigilance techniques and exercises educating in college medical clinics or by scholarly social orders in pediatrics, clinical pharmacology, and drug store; strategies for ADR observing ought to be straightforward, conceivably mechanized, normalized, and universally acknowledged; pharmacovigilance exercises ought to have the option to depend on sufficient foundation, in light of electronic organizations, arrangement of local joint efforts and associations. Besides, it has been accounted for that foundation of explicitly devoted projects brought about expanded mindfulness and detailing of suspected ADRs in kids[40].

ACKNOWLEDGMENT

We would like to express our special thanks of gratitude to all the respected authors of all references from where we have reviewed our topic of interest. We came to know a lot of information and we are thankful to them. Secondly we would like to thank our parents and friends who helped us in finalizing the project and doing the work within the limited time frame.

REFERENCES

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. Jama. 1998 Apr 15;279(15):1200-5.
2. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of hospital admission: prospective analysis of 18 820 patients. Bmj. 2004 Jul 1;329(7456):15-9.
3. Rzany B, Mockenhaupt M, Baur S, Schroder W, Stocker U, Mueller J, Hollander N, Bruppacher R, Schopf E. Epidemiology of erythema exsudativum multiforme majus. Stevens-Johnson syndrome and toxic epidermal necrolysis in Germany (1990-1992): Structure and results of a population-based registry. 1990.
4. Mittmann N, Knowles SR, Gomez M, Fish JS, Cartotto R, Shear NH. Evaluation of the extent of under-reporting of serious adverse drug reactions. Drug safety. 2004 Jun;27(7):477-87.
5. Neville KA, Becker ML, Glodman JL, et al. Developmental pharmacogenomics. PedatrAnesth2011;21:255-65.
6. Pandolfini C, Bonati M. A literature review on off-label drug use in children. European journal of pediatrics. 2005 Sep 1;164(9):552-8.
7. World Health Organization (WHO). The importance of pharmacovigilance – Safety monitoring of medicinal products. Geneva: WHO, 2002.
8. Clarkson A, Ingleby E, Choonara I, Bryan P, Arlett P. A novel scheme for the reporting of adverse drug reactions. Archives of disease in childhood. 2001 Apr 1;84(4):337-9.
9. Clavenna A, Bonati M. Adverse drug reactions in childhood: a review of prospective studies and safety alerts. Archives of disease in childhood. 2009 Sep 1;94(9):724-8.

10. Priyadharsini R, Surendiran A, Adithan C, Sreenivasan S, Sahoo FK. A study of adverse drug reactions in pediatric patients. Journal of pharmacology & pharmacotherapeutics. 2011 Oct;2(4):277.
11. Cuzzolin L. Off-label drug in the newborn. Journal of Pediatric and Neonatal Individualized Medicine (JPNIM). 2014 Oct 3;3(2):e030224-.
12. MacLeod S, Peterson R, Wang Y, Li Z, Gui Y, Schaller J. Challenges in international pediatric pharmacology. Pediatric drugs. 2007 Jul;9(4):215-8.
13. Shetti S, Kumar CD, Sriwastava NK, Sharma IP. Pharmacovigilance of herbal medicines: Current state and future directions. Pharmacognosy Magazine. 2011 Jan;7(25):69.
14. Etwel FA, Rieder MJ, Bend JR, Koren G. A surveillance method for the early identification of idiosyncratic adverse drug reactions. Drug safety. 2008 Feb;31(2):169-80.
15. Paolucci P, Jones KP, Garcinuno MD, Catapano M, Iolascon A, Ceci A. Challenges in prescribing drugs for children with cancer. The Lancet Oncology. 2008 Feb 1;9(2):176-83.
16. Marrett L, De P, Dryer D. Canadian Cancer Society's Steering Committee: Canadian Cancer Statistics 2010. Toronto: Canadian Cancer Society. 2010;1.
17. Sankila R, Jimenez MM, Miljus D, Pritchard-Jones K, Steliarova-Foucher E, Stiller C. Geographical comparison of cancer survival in European children (1988–1997): report from the Automated Childhood Cancer Information System project. European Journal of Cancer. 2006 Sep 1;42(13):1972-80.
18. Ross CJ, Carleton B, Warn DG, Stenton SB, Rassekh SR, Hayden MR. Genotypic approaches to therapy in children: a national active surveillance network (GATC) to study the pharmacogenomics of severe adverse drug reactions in children. Annals of the New York Academy of Sciences. 2007 Sep;1110(1):177-92.
19. Carleton BC, Poole RL, Smith MA, Leeder JS, Ghannadan R, Ross CJ, Phillips MS, Hayden MR. Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals. Pharmacoepidemiology and drug safety. 2009 Aug;18(8):713-21.
20. Menniti-lppolito F, Raschetti R, Da Cas R, Giaquinto C, Cantarutti L. Active monitoring of adverse drug reactions in children. The Lancet. 2000 May 6;355(9215):1613-4.
21. Lexchin J. Is there still a role for spontaneous reporting of adverse drug reactions?.Cmaj. 2006 Jan 17;174(2):191-2.
22. Carleton BC, Smith MA, Gelin MN, Heathcote SC. Paediatric adverse drug reaction reporting: understanding and future directions. Journal of Population Therapeutics and Clinical Pharmacology. 2007;14(1).
23. Kearns GL. Impact of developmental pharmacology on pediatric study design: overcoming the challenges. Journal of allergy and clinical immunology. 2000 Sep 1;106(3):S128-38.
24. MacLeod S. Therapeutic drug monitoring in pediatrics: how do children differ?. Therapeutic drug monitoring. 2010 Jun 1;32(3):253-6.
25. Carleton B, Lesko A, Milton J, Poole RL. Active surveillance systems for pediatric adverse drug reactions: an idea whose time has come. Current therapeutic research. 2001 Oct 1;62(10):738-42.
26. Wong IC, Ghaleb MA, Franklin BD, Barber N. Incidence and nature of dosing errors in paediatric medications. Drug safety. 2004 Aug;27(9):661-70.
27. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. British journal of clinical pharmacology. 2001 Jul;52(1):77-83.
28. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Annals of internal medicine. 2004 May 18;140(10):795-801.
29. Honigman B, Light P, Pulling RM, Bates DW. A computerized method for identifying incidents associated with adverse drug events in outpatients. International journal of medical informatics. 2001 Apr 1;61(1):21-32.
30. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. The lancet. 2000 Oct 7;356(9237):1255-9.
31. Neubert A, Dormann H, Weiss J, Criegee-Rieck M, Ackermann A, Levy M, Brune K, Rascher W. Are computerised monitoring systems of value to improve pharmacovigilance in paediatricpatients?. European journal of clinical pharmacology. 2006 Nov;62(11):959-65.
32. Howland RH. Pharmacogenetics and Pharmacovigilance. Drug Safety 2009;32:265-70.
33. Hauben M, Aronson JK. Defining 'signal'and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug safety. 2009 Feb;32(2):99-110.

34. Johann-Liang R, Wyeth J, Chen M, Cope JU. Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003–2007. Pharmacoepidemiology and drug safety. 2009 Jan;18(1):24-7.
35. Edwards IR. What are the real lessons from Vioxx®?. Drug safety. 2005 Aug;28(8):651-8.
36. Castro-Pastrana LI, Carleton BC. Improving pediatric drug safety: need for more efficient clinical translation of pharmacovigilance knowledge. Journal of Population Therapeutics and Clinical Pharmacology. 2011;18(1).
37. van Puijenbroek E, Conemans J, van Grootheest K. Spontaneous Reports and Pharmacogenetics. Drug safety. 2009 Apr;32(4):357-8.
38. Impicciatore M. Pharmacogenomic can give children safer medicines. Archives of disease in childhood. 2003 Apr 1;88(4):366-.
39. Leeder JS. Developmental and pediatric pharmacogenomics. Pharmacogenomics. 2003 May 1;4(3):331-41.
40. Clarkson A, Conroy S, Burroughs K, Choonara I. Surveillance for adverse drug reactions in children: a paediatric regional monitoring centre. Paediatric and Perinatal Drug Therapy. 2004 Jun;6:20-3.